Qualitative Interviews Exploring Adverse Event Mitigation Strategies in Adults Receiving Amikacin Liposome Inhalation Suspension.

ABSTRACT:

Introduction

This study aimed to gain insight from patients with refractory Mycobacterium avium complex lung disease (MAC-LD) into strategies used to manage adverse events (AEs) associated with amikacin liposome inhalation suspension (ALIS).

Methods

We conducted semi-structured interviews with US patients with refractory MAC-LD prescribed ALIS in a real-world setting. Interview transcripts were analyzed and coded to identify patterns in participants' descriptions of their ALIS treatment experiences, including AEs and their disruptiveness, and AE mitigation strategies, including participants' ratings of strategies' effectiveness. Concept saturation was also assessed.

Results

Twenty participants (mean age 48.7 years; 80% women; mean ALIS duration 5.45 months) were inter

SUBMITTER: Ali J 

PROVIDER: S-EPMC11339226 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature